PMID- 35316619
OWN - NLM
STAT- MEDLINE
DCOM- 20220414
LR  - 20240214
IS  - 1878-1551 (Electronic)
IS  - 1534-5807 (Print)
IS  - 1534-5807 (Linking)
VI  - 57
IP  - 6
DP  - 2022 Mar 28
TI  - The central moTOR of metabolism.
PG  - 691-706
LID - S1534-5807(22)00126-5 [pii]
LID - 10.1016/j.devcel.2022.02.024 [doi]
AB  - The protein kinase mechanistic target of rapamycin (mTOR) functions as a central 
      regulator of metabolism, integrating diverse nutritional and hormonal cues to 
      control anabolic processes, organismal physiology, and even aging. This review 
      discusses the current state of knowledge regarding the regulation of mTOR 
      signaling and the metabolic regulation of the four macromolecular building blocks 
      of the cell: carbohydrate, nucleic acid, lipid, and protein by mTOR. We review 
      the role of mTOR in the control of organismal physiology and aging through its 
      action in key tissues and discuss the potential for clinical translation of mTOR 
      inhibition for the treatment and prevention of diseases of aging.
CI  - Published by Elsevier Inc.
FAU - Simcox, Judith
AU  - Simcox J
AD  - Department of Biochemistry, University of Wisconsin-Madison, Madison, WI, USA. 
      Electronic address: jsimcox@wisc.edu.
FAU - Lamming, Dudley W
AU  - Lamming DW
AD  - William S. Middleton Memorial Veterans Hospital, Madison, WI, USA; Department of 
      Medicine, University of Wisconsin-Madison, Madison, WI, USA. Electronic address: 
      dlamming@medicine.wisc.edu.
LA  - eng
GR  - R56 AG056771/AG/NIA NIH HHS/United States
GR  - I01 BX004031/BX/BLRD VA/United States
GR  - R01 AG056771/AG/NIA NIH HHS/United States
GR  - K12 AR084227/AR/NIAMS NIH HHS/United States
GR  - R21 AG061635/AG/NIA NIH HHS/United States
GR  - R01 AG062328/AG/NIA NIH HHS/United States
GR  - RF1 AG056771/AG/NIA NIH HHS/United States
GR  - P30 DK020579/DK/NIDDK NIH HHS/United States
GR  - R01 DK125859/DK/NIDDK NIH HHS/United States
GR  - K12 HD101368/HD/NICHD NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
DEP - 20220321
PL  - United States
TA  - Dev Cell
JT  - Developmental cell
JID - 101120028
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Mechanistic Target of Rapamycin Complex 1/metabolism
MH  - *Signal Transduction/physiology
MH  - Sirolimus/pharmacology
MH  - *TOR Serine-Threonine Kinases/metabolism
PMC - PMC9004513
MID - NIHMS1791483
OTO - NOTNLM
OT  - amino acids
OT  - lipids
OT  - mTOR
OT  - mTORC1
OT  - mTORC2
OT  - metabolism
OT  - protein
OT  - rapamycin
COIS- Declaration of interests D.W.L. has received funding from and is a scientific 
      advisory board member of Aeovian Pharmaceuticals, which seeks to develop novel, 
      selective mTOR inhibitors for the treatment of various diseases.
EDAT- 2022/03/23 06:00
MHDA- 2022/04/15 06:00
PMCR- 2023/03/28
CRDT- 2022/03/22 20:06
PHST- 2021/12/10 00:00 [received]
PHST- 2022/02/20 00:00 [revised]
PHST- 2022/02/24 00:00 [accepted]
PHST- 2022/03/23 06:00 [pubmed]
PHST- 2022/04/15 06:00 [medline]
PHST- 2022/03/22 20:06 [entrez]
PHST- 2023/03/28 00:00 [pmc-release]
AID - S1534-5807(22)00126-5 [pii]
AID - 10.1016/j.devcel.2022.02.024 [doi]
PST - ppublish
SO  - Dev Cell. 2022 Mar 28;57(6):691-706. doi: 10.1016/j.devcel.2022.02.024. Epub 2022 
      Mar 21.